Prognostic value of whole-body dynamic 18F-FDG PET/CT Patlak in diffuse large B-cell lymphoma

ObjectiveThis study aimed to investigate the value of interim whole-body dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) Patlak parameters for predicting prognosis patients with diffuse large B-cell lymphoma. To estimate predictive 18F-FDG PET/CT parameter 2-year progression-free survival (PFS) and overall (OS).MethodsThis reports findings 67 lymphoma (DLBCL). These underwent scans from June 2021 January 2023 at Department Nuclear Medicine, First Affiliated Hospital Anhui Medical University. The values SUVmax, Kimax model combining treatment response on was analyzed using receiver operating characteristic (ROC) curves. Kaplan-Meier curves log-rank tests were used analysis. Univariate multivariate analyses performed screen independent prognostic risk factors.ResultsAfter a median follow-up 18 months, 21 (31.3%) experienced disease recurrence or death. cut-off maximum standard uptake (SUVmax) net glucose rate (Kimax) 6.1 0.13 μmol min−1·ml−1, respectively. Ann Arbor stage, IPI, associated PFS OS in univariate However, only influences analysis.ConclusionInterim imaging has significant DLBCL. Among them, showed best compared SUVmax response. established by allowed accurate stratification